ArticleClinical rheumatology2026
Structural remission rate and factors associated with radiographic progression in patients with rheumatoid arthritis treated with sarilumab in clinical practice.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClinical trials have demonstrated the efficacy of sarilumab in preventing radiographic progression. This study investigated the structural remission rate and factors associated with radiographic progression in patients with rheumatoid arthritis (RA) treated with sarilumab in clinical practice.
methodsOf 114 patients treated with sarilumab across four centers, 59 with radiographic assessments at baseline and Week 52 were included. Radiographic progression was assessed using the van der Heijde-modified Total Sharp score (mTSS). Patients were divided into methotrexate (MTX) + and MTX - groups; the structural remission rate (ΔmTSS ≤ 0.5) and associated factors were analyzed.
resultsThe median age was 69.0 years, median disease duration 10.0 years, mean disease activity score 28-erythrocyte sedimentation rate 4.94, and median modified Health Assessment Questionnaire 0.5, with no differences between groups. Baseline median erosion score was 21.0, joint space narrowing score was 22.0, and mTSS was 37.0. At Week 52, the mean changes were: erosion 0.33, joint space narrowing score 0.18, and mTSS 0.51, with a structural remission rate of 78.0%, 82.4% for the MTX + group, and 76.2% for the MTX - group. The mean change in joint space narrowing score was higher in the MTX - group (0.42) than in the MTX + group (- 0.20) (p = 0.038). Baseline glucocorticoid (GC) use was associated with radiographic progression (odds ratio, 13.1; 95% confidence interval, 2.51-68.9; p = 0.002).
conclusionsSarilumab was associated with limited radiographic progression in patients with RA in clinical practice. Associations with MTX use and baseline GC exposure should be interpreted cautiously given the observational design. Key Points • This study reports the structural remission rate and factors associated with radiographic progression in patients with rheumatoid arthritis treated with sarilumab in clinical practice. • The structural remission rate for sarilumab was 78.0%. The change in the joint space narrowing score was significantly higher in the MTX- group (0.42 ± 1.34) compared with the MTX + group (- 0.20 ± 1.22). • Glucocorticoid use was associated with radiographic progression at 52 weeks (odds ratio, 13.1).
Indexed as
Identifiers
41563698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.